Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 601 - 625 of 1992 in total

Tenofovir alafenamide

Tenofovir alafenamide is a novel tenofovir prodrug developed in order to improve renal safety when compared to the counterpart tenofovir disoproxil. Both of these prodrugs were first created to cover the polar phosphonic acid group on tenofovir by using a novel oxycarbonyloxymethyl linkers to improve the oral bioavailability and intestinal...
Approved
Matched Description: … group on tenofovir by using a novel oxycarbonyloxymethyl linkers to improve the oral bioavailability and ... [L4388,L9010] Tenofovir alafenamide was developed by Gilead Sciences Inc and granted FDA approval ... alafenamide is indicated to treat chronic hepatitis B,[L6241] treat HIV-1,[L4388,L6277,L6280,L6283] and …
Matched Categories: … Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor ... Tenofovir and prodrugs ... Amino Acids, Peptides, and Proteins ... emtricitabine and tenofovir alafenamide ... emtricitabine, tenofovir alafenamide and rilpivirine …

Olaparib

Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Olaparib...
Approved
Matched Description: … Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and ... [L41100, L40908, L43792] It was first approved by the FDA and EU in December 2014,[A246020] and by Health ... [L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Micafungin

Micafungin is an antifungal drug. It belongs to the antifungal class of compounds known as echinocandins and exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall.
Approved
Investigational
Matched Description: … It belongs to the antifungal class of compounds known as echinocandins and exerts its effect by inhibiting …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Sulfinpyrazone

A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.
Approved
Matched Description: … It lacks anti-inflammatory, analgesic, and diuretic properties. …

Bromhexine

Bromhexine is mucolytic agent used for a variety of respiratory conditions associated with increased mucus secretion. It is derived from the Adhatoda vasica plant and aids in the clearance of excess mucus, improving breathing and reducing cough. It was introduced into the market in 1963, and is widely available as...
Approved
Matched Description: … and reducing cough. ... prevention and treatment of COVID-19 due to their interactions with cell receptors in the lungs. ... It was introduced into the market in 1963, and is widely available as an over-the-counter drug in many …
Matched Categories: … Cough and Cold Preparations …

Sildenafil

In eliciting its mechanism of action, sildenafil ultimately prevents or minimizes the breakdown of cyclic guanosine monophosphate (cGMP) by inhibiting cGMP specific phosphodiesterase type 5 (PDE5) [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. The result of doing so allows cGMP present in both the penis and pulmonary vasculature to...
Approved
Investigational
Matched Description: … it to grow in size and become erect and rigid [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614 ... The result of doing so allows cGMP present in both the penis and pulmonary vasculature to elicit smooth ... and the increased flow of blood into the spongy erectile tissue of the penis that consequently allows …

Allopurinol

Gout is a disease that occurs by the deposition of monosodium urate crystals (MSU) in body tissues, especially around joints . This disease has been well-documented in historical medical records and appears in the biographies of several prominent, historically recognized individuals . Allopurinol is a xanthine oxidase enzyme inhibitor that...
Approved
Matched Description: … This disease has been well-documented in historical medical records and appears in the biographies of ... It was initially approved by the FDA in 1966 [L5674] and is now formulated by several manufacturers [ ... enzyme inhibitor that is considered to be one of the most effective drugs used to decrease urate levels and …

Enasidenib

Enasidenib is an orally available treatment for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with specific mutations in the isocitrate dehydrogenase 2 (IDH2) gene, which is a recurrent mutation detected in 12-20% of adult patients with AML [A20344, A20345]. Patients eligible for this treatment...
Approved
Investigational
Matched Description: … Food and Drug Administration on August 1, 2017. ... First developed by Agios Pharmaceuticals and licensed to Celgene, enasidenib was approved by U.S. ... This small molecule acts as an allosteric inhibitor of mutant IDH2 enzyme to prevent cell growth, and …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Sulfadoxine

A long acting sulfonamide that is used, usually in combination with other drugs, for respiratory, urinary tract, and malarial infections.
Approved
Investigational
Matched Description: … sulfonamide that is used, usually in combination with other drugs, for respiratory, urinary tract, and …
Matched Categories: … Genito Urinary System and Sex Hormones ... artesunate, sulfadoxine and pyrimethamine ... Gynecological Antiinfectives and Antiseptics ... Antiparasitic Products, Insecticides and Repellents …

Potassium gluconate

Potassium gluconate is a salt of DB01345 and is classified as a food additive by the FDA . It is also used as a potassium supplement . Potassium is an essential nutrient. It is the most abundant cation in the intracellular fluid, where it plays a key role in maintaining...
Approved
Matched Description: … Potassium gluconate is a salt of [DB01345] and is classified as a food additive by the FDA [L2654]. ... Potassium gluconate is believed to be more palatable and non-acidifying than potassium chloride (KCl) ... potassium chloride, but many other forms—including potassium citrate, phosphate, aspartate, bicarbonate, and …
Matched Mixtures name: … Cal-mag Plus K, Mn and Zn Caplets ... Spectra 301 Vitamin and Mineral Supp ... Multivitamins and Minerals for Young Men …
Matched Categories: … Alimentary Tract and Metabolism …

Vutrisiran

Vutrisiran is a double-stranded small interfering ribonucleic acid (siRNA) that targets wild-type and mutant transthyretin (TTR) messenger RNA (mRNA). This siRNA therapeutic is indicated for the treatment of neuropathies associated with hereditary transthyretin-mediated amyloidosis (ATTR), a condition caused by mutations in the TTR gene. More than 130 TTR mutations have...
Approved
Investigational
Matched Description: … [A249025,L42065] This delivery platform gives vutrisiran high potency and metabolic stability, and allows ... Vutrisiran is a double-stranded small interfering ribonucleic acid (siRNA) that targets wild-type and ... prevalent among hereditary ATTR patients with polyneuropathy, especially in Portugal, France, Sweden, and …
Matched Categories: … Nucleic Acids, Nucleotides, and Nucleosides …

Pitavastatin

Pitavastatin, also known as the brand name product Livalo, is a lipid-lowering drug belonging to the statin class of medications. By inhibiting the endogenous production of cholesterol within the liver, statins lower abnormal cholesterol and lipid levels and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competitively...
Approved
Matched Description: … lipid levels and ultimately reduce the risk of cardiovascular disease. ... studies to significantly reduce the risk of development of CVD and all-cause mortality. ... inhibiting the endogenous production of cholesterol within the liver, statins lower abnormal cholesterol and …

Lorlatinib

Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive...
Approved
Investigational
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Sebelipase alfa

The lysosomal acid lipase (LAL) enzyme is found in lysosomes and is primarily responsible for the metabolism of lipids, and its absence or deficiency results in the accumulation of lipids in various organs. This lipid accumulation can lead to end-organ damage in the form of liver dysfunction or malabsorption secondary...
Approved
Investigational
Matched Description: … It was first approved by both the FDA and EMA in 2015 and is marketed under the brand name Kanuma (Alexion ... of lipids, and its absence or deficiency results in the accumulation of lipids in various organs. ... The lysosomal acid lipase (LAL) enzyme is found in lysosomes and is primarily responsible for the metabolism …
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism …

Lipegfilgrastim

Lipegfilgrastim, previously known as XM22, is a pegylated, recombinant granulocyte colony-stimulating factor (G-CSF) that was synthetized using a highly site-specific glycoPEGylation technology . It is used as an alternate to DB00019 for prophylactic use in cancer patients receiving chemotherapy and at risk for developing chemotherapy-induced neutropenia. Since July 2013, lipegfilgrastim...
Approved
Investigational
Matched Description: … Neutropenia and febrile neutropenia (FN) are frequent and potentially fatal complications that occur ... life-threatening infection and sepsis. ... It aims to reduce the duration of neutropenia and the incidence of febrile neutropenia. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Intercellular Signaling Peptides and Proteins …

Eladocagene exuparvovec

Eladocagene exuparvovec is a recombinant adeno-associated virus-2 (AAV2)-based gene therapy that expresses human aromatic L-amino acid decarboxylase (AADC), and it is used to treat AADC deficiency, a fatal and rare genetic disorder that causes severe disability in pediatric patients.[L43642,L43672] Patients with AADC have mutations in the dopa decarboxylase (DDC) gene...
Approved
Investigational
Matched Description: … Eladocagene exuparvovec is a recombinant adeno-associated virus-2 (AAV2)-based gene therapy that expresses human ... aromatic L-amino acid decarboxylase (AADC), and it is used to treat AADC deficiency, a fatal and rare ... neurotransmitter production, decrease neurotransmitter catabolism via monoamine oxidase (MAO) inhibition and …
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism …

Fluticasone furoate

Fluticasone furoate is a synthetic glucocorticoid available as an inhaler and nasal spray for various inflammatory indications[FDA Label] . Fluticasone furoate was first approved in 2007 .
Approved
Matched Description: … Fluticasone furoate is a synthetic glucocorticoid available as an inhaler and nasal spray for various …
Matched Mixtures name: … Fluticasone Furoate and Vilanterol ... Fluticasone Furoate and Vilanterol …
Matched Categories: … vilanterol and fluticasone furoate ... vilanterol, umeclidinium bromide and fluticasone furoate …

Ceftolozane

Ceftolozane is a semi-synthetic broad-spectrum fifth generation cephalosporin. It was approved by the FDA in 2014 for use in combination with Tazobactam for the treatment of serious infections, such as intra-abdominal infections and complicated urinary tract infections. The manufacturer of this drug is Cubist Pharmaceuticals. Most recently, in June 2019,...
Approved
Investigational
Matched Description: … and mortality in hospitalized patients and the use of ceftolozane-tazobactam offers effective activity ... 2019, ceftolozane-tazobactam was approved for the treatment of hospital-acquired bacterial pneumonia and ... combination with [Tazobactam] for the treatment of serious infections, such as intra-abdominal infections and …

Tagraxofusp

Tagraxofusp is a CD123-directed cytotoxin. It is a fusion protein composed of a human interleukin-3 (IL-3) that is genetically fused to the catalytic and translocation domains of truncated diphtheria toxin (DT) produced in Escherichia coli.[A253762, A253887, L43702] Tagraxofusp received its first global approval by the FDA on December 21, 2018...
Approved
Investigational
Matched Description: … and translocation domains of truncated diphtheria toxin (DT) produced in _Escherichia coli_. ... It is a fusion protein composed of a human interleukin-3 (IL-3) that is genetically fused to the catalytic …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Ocrelizumab

Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-humanized CD20 antibodies such as rituximab, ocrelizumab is...
Approved
Investigational
Matched Description: … inflammatory, autoimmune disease of the central nervous system that leads to neurological disabilities and ... Health Canada in August 2017, making the drug the first available treatment for PPMS in both the US and ... In phase 3 clinical trials of patients with PPMS, treatment with ocrelizumab led to lower clinical and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Lumacaftor

Lumacaftor is a drug used in combination with DB08820 as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic...
Approved
Matched Description: … Approved for use by the Food and Drug Administration in July 2015 and by Health Canada in January 2016 ... and trafficking of mature protein to the cell surface. ... consequently abnormal fluid and ion transport across cell membranes. …
Matched Categories: … ivacaftor and lumacaftor …

Fidanacogene elaparvovec

Fidanacogene elaparvovec is a liver-specific adeno-associated virus (AAV) vector containing a codon-optimized human coagulation FIX gene that was investigated as a potential treatment for hemophilia B. Hemophilia B is a rare X-linked genetic disorder characterized by abnormal coagulation due to dysfunctional coagulation factor IX with a male incidence estimated to...
Approved
Investigational
Matched Description: … Fidanacogene elaparvovec is a liver-specific adeno-associated virus (AAV) vector containing a codon-optimized human ... the level of factor IX activity in the blood plasma, ranging from increased bleeding after injuries and ... surgical operations to spontaneous bleeding, hemorrhages in soft tissues or joints, and severe subcutaneous …

Clascoterone

Clascoterone (cortexolone 17α-propionate, CB-03-01) is a novel antagonist of androgen receptors. It binds to androgen receptors with high affinity. By competing with androgens for binding to androgen receptors, clascoterone works by blocking the androgen receptor signalling cascades that promote acne pathogenesis, such as sebaceous gland proliferation, excess sebum production, and...
Approved
Investigational
Matched Description: … female patients 12 years and older. ... FDA approved clascoterone for the first-in-class topical treatment of acne (acne vulgaris) in male and ... cascades that promote acne pathogenesis, such as sebaceous gland proliferation, excess sebum production, and …
Matched Categories: … Hormones, Hormone Substitutes, and Hormone Antagonists …

Rizatriptan

Rizatriptan is a second-generation triptan and a selective 5-HT1B and 5-HT1D receptor agonist. Used in the treatment of migraines, rizatriptan was first approved in the US in 1998. Rizatriptan is available in oral tablets, orally disintegrating tablets (wafers), and oral film formulations.
Approved
Matched Description: … Rizatriptan is a second-generation triptan [A258918] and a selective 5-HT1B and 5-HT1D receptor ... [L46018] Rizatriptan is available in oral tablets, orally disintegrating tablets (wafers), and oral film …
Matched Categories: … Serotonin-1b and Serotonin-1d Receptor Agonist …

Milnacipran

Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment of depression [F3928, F3934, A175786, A175951]. Furthermore, in 2009 the US FDA approved milnacipran for the additional indication of...
Approved
Investigational
Matched Description: … Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents ... in this category was originally developed for and continues to be approved and indicated for the treatment ... unique characteristic among SNRIs to elicit a relatively balanced reuptake inhibition of both serotonin and …
Matched Categories: … Milnacipran and enantiomer ... Serotonin and Noradrenaline Reuptake Inhibitors …
Displaying drugs 601 - 625 of 1992 in total